Eisai Company, Limited

Esai Co., Ltd.

Eisai Inc.

Shigeru Souda

Shuhei Miyazawa

Naoyuki Shimomura

Isao Yamatsu

Yoshimasa Machida

Kouichi Katayama

Shinya Abe

Hiroyuki Yoshimura

Katsuya Tagami

Tetsuya Kawahara

Mitsuaki Miyamoto

Koukichi Harada

Kazuo Okano

Osamu Asano

Toshihiko Kaneko

Seiichiro Nomoto

Norihiro Ueda

Makoto Okita

Tsuneo Wakabayashi

Satoshi Katayama

Kouji Yamada

Kenzo Muramoto

Kazutoshi Miyake

Nobuhisa Watanabe

Tsutomu Kawata

Hideyuki Adachi

Hiroshi Obaishi

Yasutaka Takase

Hajime Tsunoda

Junsaku Nagaoka

Yoshimori Sakuma

Hironori Ikuta

Richard S Clark

Hisashi Shibata

Manabu Murakami

Masatoshi Fujimoto

Kiyoshi Oketani

Hideaki Fujisaki

Fumihiro Ozaki

Keiji Ishibashi

Hiroki Ishihara

Takao Saeki

Hidetoshi Kawashima

Masayuki Matsukura

Toshiaki Ogawa

Yasuhiro Kabasawa

Noriyasu Hirose

Makoto Kaino

Tsutomu Yoshimura

Naoko Nagaoka

Hiromasa Suzuki

Kohtaro Kodama

Takeshi Suzuki

Shigeki Hibi

Yasushi Okamoto

Takashi Yamanaka

Kenji Hayashi

Hitoshi Oinuma

Teiji Kimura

Ieharu Hishinuma

Junichi Nagakawa

Naoki Yoneda

Kenichi Chiba

Hiroshi Shirota

Kaname Miyamoto

Ryoichi Hashida

Hideki Ono

Masayuki Tanaka

Masaki Goto

Hideto Ohhara

Makoto Matsui

Hideki Sakurai

Yasunori Akita

Hisatoshi Mochida

Tadakazu Tokumura

Shigeto Negi

Yasuhiro Akiyama

Kazuki Miyazaki

Yoshiharu Daiku

Kenichi Nomoto

Yoshio Fukuda

Takashi Hasegawa

Masanori Mizuno

Naoki Kobayashi

Issei Ohtsuka

Yoshihito Eguchi

Katsuhiro Moriya

Shizuo Kuriyama

Hironobu Hiyoshi

Tadanobu Takamura

Manabu Shirato

Ichirou Yoshida

Koichi Nose

Naoya Kishi

Makoto Kotake

Nobuyuki Mori

Mamoru Saito

Toshiyuki Matsuoka

Shinji Suda

Masaru Sato

Fused pyridazine compounds

Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are described.

Pyridine derivatives having anti-ulcerative activity

An ulcer and/or gastritis are prevented, improved or treated by administering a pharmacologically effective amount of the compound having the below shown formula (I) or (II) or a pharmacologically acceptable salt thereof to a mammal suffering from such a disease. ##STR1##

Antimicrobial agent

Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are disclosed.

The present invention provides a nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof which is useful for various ischemic heart diseases and the like: ##STR1## �in formula (1), ring A represents a benzene ring, a pyridine ring or a cyclohexane ring; ring B represents a pyridine ring, a pyrimidine ring or an imidazole ring, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent each a hydrogen atom, a halogen atom or a group such as a lower alkoxy group; R.sup.5 represents a group represented by the formula --NR.sup.11 R.sup.12 (wherein R.sup.11 and R.sup.12 represent each a hydrogen atom or a group such as a lower alkyl group) or the like; and R.sup.6 represents a group represented by the formula ##STR2## (wherein R.sup.19 represents a hydrogen atom, a lower alkyl group or the like; R.sup.20, R.sup.21 and R.sup.22 represent each a hydrogen atom, a halogen atom, a hydroxyl group or the like; and r represents 0 or an integer of 1 to 8)!.

Quinazoline derivatives

Phosphonic acid derivatives

Anthranilic acid derivatives

Nitrogen-containing fused-heterocycle compounds

A pyridine compound having the formula is disclosed and useful to treat the peptic ulcer. ##STR1## wherein R.sup.1 and R.sup.2 which may be the same or different are each a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogenated lower alkyl group, or a halogen atom, R.sup.3 and R.sup.4 which may be the same or different are each a hydrogen atom or a lower alkyl group, X is a group represented by the formula --S--, a group represented by the formula ##STR2## or a group represented by the formula ##STR3## and n is an integer of 1 to 6, provided that R.sup.3 and R.sup.4 are not simultaneously hydrogen atoms when n is 1.

Pyridine derivative and therapeutic agent for ulcer comprising the same

The present invention provides a nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof which is useful for various ischemic heart diseases and the like: ##STR1## �in formula (1), ring A represents a benzene ring, a pyridine ring or a cyclohexane ring: ring B represents a pyridine ring, a pyrimidine ring or an imidazole ring, R.sup.1, R.sup.2, R.sup.3 R.sup.4, R.sup.5 and R.sup.6 are described herein.

Benzimidazoles for ischemic heart conditions

The present invention relates to an amino acid derivative having an angiotensin I-converting enzyme inhibition activity, a vasopressin antagonism and an atrial natriuretic peptide hydrolase inhibition activity. This amino acid derivative is represented by the following general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom or an acyl group; R.sup.2 represents a hydrogen atom, a lower alkyl group, a cycloalkyl group, an ary group which may have a substituent, a heteroaryl group which may have a substituent, an arylalkyl group which may have a substituent or a heteroarylalkyl group which may have a substituent;

Amino acid derivative

Quinazoline compounds

To provide a novel cyclohexane derivative, a cyclohexane derivative is defined by the formula (I) or a pharmacologically acceptable salt thereof: ##STR1## (wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents hydrogen or lower alkyl; R.sup.3 represents optionally substituted aryl or optionally substituted heteroaryl; X represents oxygen or sulfur; and Y represents a group represented by the formula: ##STR2## or the like). The compound of the present invention is useful as a preventive and therapeutic agent for diseases against which a potassium channel opening action is efficacious.

Cyclohexane derivatives

Propenoic acid derivatives of the formula: ##STR1## where R.sup.15 and R.sup.17 are aryl or heteroalkyl groups and R.sup.16 and R.sup.18 are hydrogen, a lower alkyl or the like are intermediates used to prepare pharmaceutically active diazole propenoic acid compounds.

Diazole-propenoic acid compounds

Growing community of inventors

Ibaraki, Japan

Shigeru Souda